Effect of Quadro-Iliac Plane Block on Recovery After Laparoscopic Hysterectomy (QIPB-TLH)
Effect of Quadro-Iliac Plane Block on Postoperative Quality of Recovery in Patients Undergoing Laparoscopic Hysterectomy: A Prospective, Randomized, Controlled Clinical Trial
This prospective, randomized, controlled clinical trial aims to evaluate the effect of an ultrasound-guided bilateral quadro-iliac plane block (QIPB) on postoperative recovery quality in patients undergoing elective total laparoscopic hysterectomy.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Total laparoscopic hysterectomy (TLH) is a minimally invasive surgical procedure; however, patients may experience postoperative pain originating from abdominal incisions, visceral manipulation, and pneumoperitoneum-related irritation. Inadequate postoperative pain management may negatively affect patient comfort, early mobilization, and overall quality of recovery. Although opioids provide effective analgesia, their use may be associated with nausea, vomiting, sedation, and other adverse effects. Therefore, multimodal and opioid-sparing analgesic strategies are important components of perioperative care.
The quadro-iliac plane block (QIPB) is an ultrasound-guided fascial plane block targeting the anatomical plane near the caudal attachment of the quadratus lumborum muscle to the iliac crest. Previous clinical studies have suggested that QIPB may improve postoperative analgesia and reduce opioid requirements in selected surgical populations. However, its effect on postoperative recovery quality following total laparoscopic hysterectomy remains to be investigated.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Betül Kozanhan, M.D
- Telefonnummer: 0 (332) 310 50 00
- E-Mail: betulkozanhan@gmail.com
Studienorte
-
-
-
Konya, Türkei (türkiye)
- Betul Kozanhan
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Female patients aged 18 years or older.
- Scheduled for elective total laparoscopic hysterectomy.
- American Society of Anesthesiologists (ASA) physical status I-III.
- Body weight of at least 55 kg.
- Ability to communicate in Turkish and reliably complete the Turkish version of the Quality of Recovery-15 questionnaire (QoR-15T).
- Provision of written informed consent after receiving information about the study.
Exclusion Criteria:
- Refusal to provide informed consent or withdrawal of consent.
- Any contraindication to regional anesthesia.
- Infection at the intended block site or anatomical conditions preventing safe needle insertion.
- Severe hypersensitivity or contraindication to local anesthetics or standard/rescue analgesic medications specified in the study protocol.
- Regular opioid use or opioid use disorder.
- Regular analgesic use for chronic pain lasting longer than three months.
- Clinically significant hepatic or renal insufficiency.
- Pregnancy, postpartum period, or breastfeeding.
- Cognitive or communication impairment preventing reliable completion of QoR-15T or postoperative pain assessments.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: QIPB Group
Patients will receive bilateral ultrasound-guided quadro-iliac plane blocks with 20 mL of 0.25% bupivacaine per side in addition to standard multimodal analgesia. |
After surgery and before extubation, bilateral QIPB will be performed under ultrasound guidance. A total of 40 mL of 0.25% bupivacaine (20 mL per side) will be injected into the quadro-iliac fascial plane.
Andere Namen:
|
|
Kein Eingriff: Control Group
Patients will receive standard general anesthesia and postoperative multimodal analgesia without a regional block. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Quality of Postoperative Recovery Assessed by the QoR-15T Score
Zeitfenster: 24 hours postoperatively
|
Postoperative quality of recovery will be assessed using the validated Turkish version of the 15-item Quality of Recovery questionnaire (QoR-15T). The questionnaire consists of 15 items, each scored from 0 to 10, yielding a total score ranging from 0 to 150. Higher scores indicate better quality of recovery. The primary outcome is the total QoR-15T score at 24 hours postoperatively, compared between the bilateral Quadro-Iliac Plane Block (QIPB) group and the control group. |
24 hours postoperatively
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Postoperative Pain Intensity at Rest
Zeitfenster: PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
|
Postoperative pain intensity at rest will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. |
PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
|
|
Postoperative Pain Intensity During Movement or Coughing
Zeitfenster: PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
|
Postoperative pain intensity during movement or coughing will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. |
PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
|
|
Time to First Rescue Analgesia
Zeitfenster: Within 24 hours postoperatively
|
Time from admission to the post-anesthesia care unit (PACU) to the first administration of rescue analgesia will be recorded in minutes. |
Within 24 hours postoperatively
|
|
Time to First Opioid Analgesia
Zeitfenster: Within 24 hours postoperatively
|
Time from admission to the post-anesthesia care unit (PACU) to the first administration of intravenous opioid will be recorded in minutes. |
Within 24 hours postoperatively
|
|
Total Postoperative Tramadol Consumption
Zeitfenster: First 24 hours postoperatively
|
The total cumulative dose of intravenous opioid administered during the first 24 hours after surgery will be recorded. |
First 24 hours postoperatively
|
|
Postoperative Nausea and Vomiting
Zeitfenster: Within 24 hours postoperatively
|
Postoperative nausea and vomiting (PONV) will be assessed using a 5-point Verbal Descriptive Scale (VDS), ranging from 0 to 4 (0 = no nausea or vomiting, 1 = mild nausea, 2 = moderate nausea or vomiting, 3 = frequent vomiting, and 4 = severe vomiting). Higher scores indicate more severe symptoms. |
Within 24 hours postoperatively
|
|
Patient Satisfaction with Postoperative Analgesia
Zeitfenster: 24 hours postoperatively
|
Patient satisfaction with postoperative pain management will be assessed at 24 hours after surgery using a 5-point Likert scale ranging from 1 to 5. Higher scores indicate greater patient satisfaction with postoperative analgesia. |
24 hours postoperatively
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- KSH-QIPB-TLH-2026-01
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .